梯瓦（Teva）抗过敏喷鼻剂Qnasl获FDA批准

2012-04-16 potato 生物谷

2012年3月26日，梯瓦（Teva）公司周一宣布，FDA批准其药物Qnasl用于鼻过敏症（nasal allergy symptoms）的治疗。 Qnasl是每天一次的"干性"喷鼻剂，是通过气溶胶递送至鼻内，而不是通过水溶液或"湿性"喷雾。Qnasl是处方药，将于4月份上市，该药已被批准用于12岁及以上患有季节性过敏或常年过敏患者。梯瓦（Teva）公司的股票价格在今晨早盘交易中上涨50美分

2012年3月26日，梯瓦（Teva）公司周一宣布，FDA批准其药物Qnasl用于鼻过敏症（nasal allergy symptoms）的治疗。

Qnasl是每天一次的"干性"喷鼻剂，是通过气溶胶递送至鼻内，而不是通过水溶液或"湿性"喷雾。Qnasl是处方药，将于4月份上市，该药已被批准用于12岁及以上患有季节性过敏或常年过敏患者。

梯瓦（Teva）公司的股票价格在今晨早盘交易中上涨50美分，至43.57美元。（生物谷bioon.com）

编译自：PharmPro
http://www.pharmpro.com/News/FeedsAP/2012/03/teva-pharma-says-fda-approves-new-allergy-spray/

相关阅读

百时美施贵宝前高管出任梯瓦制药新CEO

2011年全球制药企业十大并购梯瓦占两席

梯瓦制药将从纳斯达克转往纽约上市

食用香蕉或可缓解花粉过敏症状

FDA接受缓释卡比沙明口服混悬剂治疗儿童过敏症的新药申请

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (3)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2049568, encodeId=188820495688e, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Jul 11 02:51:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839148, encodeId=e99c1839148f0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jan 09 16:51:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519131, encodeId=42ec15191316d, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-07-11 FukaiBao

#抗过敏#

40 0
[GetPortalCommentsPageByObjectIdResponse(id=2049568, encodeId=188820495688e, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Jul 11 02:51:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839148, encodeId=e99c1839148f0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jan 09 16:51:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519131, encodeId=42ec15191316d, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2013-01-09 bugit

#FDA批准#

41 0
[GetPortalCommentsPageByObjectIdResponse(id=2049568, encodeId=188820495688e, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Jul 11 02:51:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839148, encodeId=e99c1839148f0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jan 09 16:51:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519131, encodeId=42ec15191316d, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-04-18 lq1771

#ASL#

35 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

药械

梯瓦（Teva）抗过敏喷鼻剂Qnasl获FDA批准

相关资讯

科室

工具

服务